Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Aurobindo Pharma has reportedly emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5–5.5 ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

Developed by Daiichi Sankyo and Merck, it treats patients with Pretreated Extensive-Stage Small Cell Lung Cancer.

Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small ...

The erstwhile promoters of Ranbaxy Laboratories, the Singh brothers and family have been asked to pay damages of Rs 2,562.78 crore to Daiichi by an arbitration tribunal in Singapore for concealing and ...

In November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual ...

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

Daiichi Sankyo now expects Enhertu could reach JPY 195.2 billion ($1.31 billion) sales in fiscal year 2022, a big increase from the previous JPY 128.4 billion forecast.

TOKYO and SAN DIEGO, Sept. 28, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) (TSE:4568) and Ambit Biosciences (AMBI), jointly announced today that they have ...

On December 23, 2020, Daiichi Sankyo filed a petition with the U.S. Patent Office for post-grant review contesting the patentability of certain claims within the ’039 patent. About Daiichi Sankyo ...